
Global Biologics CDMO Industry Growth and Trends Forecast to 2031
Description
Summary
According to APO Research, The global Biologics CDMO market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for Biologics CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for Biologics CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for Biologics CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global manufacturers of Biologics CDMO include AGC, Boehringer Ingelheim, Fujifilm Diosynth Biotechnologies, ICON Plc, Samsung Biologics, Toyobo, AbbVie, Lonza Group AG and Thermo Fisher Scientific, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biologics CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biologics CDMO.
The Biologics CDMO market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Biologics CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Biologics CDMO Segment by Company
AGC
Boehringer Ingelheim
Fujifilm Diosynth Biotechnologies
ICON Plc
Samsung Biologics
Toyobo
AbbVie
Lonza Group AG
Thermo Fisher Scientific
WuXi Biologics
Biologics CDMO Segment by Type
Biological Agent
Biosimilar Drug
Biologics CDMO Segment by Application
Cell Therapy
Drug Development
Others
Biologics CDMO Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biologics CDMO manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Biologics CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
According to APO Research, The global Biologics CDMO market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for Biologics CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for Biologics CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for Biologics CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global manufacturers of Biologics CDMO include AGC, Boehringer Ingelheim, Fujifilm Diosynth Biotechnologies, ICON Plc, Samsung Biologics, Toyobo, AbbVie, Lonza Group AG and Thermo Fisher Scientific, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biologics CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biologics CDMO.
The Biologics CDMO market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Biologics CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Biologics CDMO Segment by Company
AGC
Boehringer Ingelheim
Fujifilm Diosynth Biotechnologies
ICON Plc
Samsung Biologics
Toyobo
AbbVie
Lonza Group AG
Thermo Fisher Scientific
WuXi Biologics
Biologics CDMO Segment by Type
Biological Agent
Biosimilar Drug
Biologics CDMO Segment by Application
Cell Therapy
Drug Development
Others
Biologics CDMO Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biologics CDMO manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Biologics CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
Table of Contents
103 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Biologics CDMO Market Size Estimates and Forecasts (2020-2031)
- 1.2.2 Global Biologics CDMO Sales Estimates and Forecasts (2020-2031)
- 1.3 Biologics CDMO Market by Type
- 1.3.1 Biological Agent
- 1.3.2 Biosimilar Drug
- 1.4 Global Biologics CDMO Market Size by Type
- 1.4.1 Global Biologics CDMO Market Size Overview by Type (2020-2031)
- 1.4.2 Global Biologics CDMO Historic Market Size Review by Type (2020-2025)
- 1.4.3 Global Biologics CDMO Forecasted Market Size by Type (2026-2031)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America Biologics CDMO Sales Breakdown by Type (2020-2025)
- 1.5.2 Europe Biologics CDMO Sales Breakdown by Type (2020-2025)
- 1.5.3 Asia-Pacific Biologics CDMO Sales Breakdown by Type (2020-2025)
- 1.5.4 South America Biologics CDMO Sales Breakdown by Type (2020-2025)
- 1.5.5 Middle East and Africa Biologics CDMO Sales Breakdown by Type (2020-2025)
- 2 Global Market Dynamics
- 2.1 Biologics CDMO Industry Trends
- 2.2 Biologics CDMO Industry Drivers
- 2.3 Biologics CDMO Industry Opportunities and Challenges
- 2.4 Biologics CDMO Industry Restraints
- 3 Market Competitive Landscape by Company
- 3.1 Global Top Players by Biologics CDMO Revenue (2020-2025)
- 3.2 Global Top Players by Biologics CDMO Sales (2020-2025)
- 3.3 Global Top Players by Biologics CDMO Price (2020-2025)
- 3.4 Global Biologics CDMO Industry Company Ranking, 2023 VS 2024 VS 2025
- 3.5 Global Biologics CDMO Major Company Production Sites & Headquarters
- 3.6 Global Biologics CDMO Company, Product Type & Application
- 3.7 Global Biologics CDMO Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Biologics CDMO Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Biologics CDMO Players Market Share by Revenue in 2024
- 3.8.3 2023 Biologics CDMO Tier 1, Tier 2, and Tier 3
- 4 Biologics CDMO Regional Status and Outlook
- 4.1 Global Biologics CDMO Market Size and CAGR by Region: 2020 VS 2024 VS 2031
- 4.2 Global Biologics CDMO Historic Market Size by Region
- 4.2.1 Global Biologics CDMO Sales in Volume by Region (2020-2025)
- 4.2.2 Global Biologics CDMO Sales in Value by Region (2020-2025)
- 4.2.3 Global Biologics CDMO Sales (Volume & Value), Price and Gross Margin (2020-2025)
- 4.3 Global Biologics CDMO Forecasted Market Size by Region
- 4.3.1 Global Biologics CDMO Sales in Volume by Region (2026-2031)
- 4.3.2 Global Biologics CDMO Sales in Value by Region (2026-2031)
- 4.3.3 Global Biologics CDMO Sales (Volume & Value), Price and Gross Margin (2026-2031)
- 5 Biologics CDMO by Application
- 5.1 Biologics CDMO Market by Application
- 5.1.1 Cell Therapy
- 5.1.2 Drug Development
- 5.1.3 Others
- 5.2 Global Biologics CDMO Market Size by Application
- 5.2.1 Global Biologics CDMO Market Size Overview by Application (2020-2031)
- 5.2.2 Global Biologics CDMO Historic Market Size Review by Application (2020-2025)
- 5.2.3 Global Biologics CDMO Forecasted Market Size by Application (2026-2031)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America Biologics CDMO Sales Breakdown by Application (2020-2025)
- 5.3.2 Europe Biologics CDMO Sales Breakdown by Application (2020-2025)
- 5.3.3 Asia-Pacific Biologics CDMO Sales Breakdown by Application (2020-2025)
- 5.3.4 South America Biologics CDMO Sales Breakdown by Application (2020-2025)
- 5.3.5 Middle East and Africa Biologics CDMO Sales Breakdown by Application (2020-2025)
- 6 Company Profiles
- 6.1 AGC
- 6.1.1 AGC Comapny Information
- 6.1.2 AGC Business Overview
- 6.1.3 AGC Biologics CDMO Sales, Revenue and Gross Margin (2020-2025)
- 6.1.4 AGC Biologics CDMO Product Portfolio
- 6.1.5 AGC Recent Developments
- 6.2 Boehringer Ingelheim
- 6.2.1 Boehringer Ingelheim Comapny Information
- 6.2.2 Boehringer Ingelheim Business Overview
- 6.2.3 Boehringer Ingelheim Biologics CDMO Sales, Revenue and Gross Margin (2020-2025)
- 6.2.4 Boehringer Ingelheim Biologics CDMO Product Portfolio
- 6.2.5 Boehringer Ingelheim Recent Developments
- 6.3 Fujifilm Diosynth Biotechnologies
- 6.3.1 Fujifilm Diosynth Biotechnologies Comapny Information
- 6.3.2 Fujifilm Diosynth Biotechnologies Business Overview
- 6.3.3 Fujifilm Diosynth Biotechnologies Biologics CDMO Sales, Revenue and Gross Margin (2020-2025)
- 6.3.4 Fujifilm Diosynth Biotechnologies Biologics CDMO Product Portfolio
- 6.3.5 Fujifilm Diosynth Biotechnologies Recent Developments
- 6.4 ICON Plc
- 6.4.1 ICON Plc Comapny Information
- 6.4.2 ICON Plc Business Overview
- 6.4.3 ICON Plc Biologics CDMO Sales, Revenue and Gross Margin (2020-2025)
- 6.4.4 ICON Plc Biologics CDMO Product Portfolio
- 6.4.5 ICON Plc Recent Developments
- 6.5 Samsung Biologics
- 6.5.1 Samsung Biologics Comapny Information
- 6.5.2 Samsung Biologics Business Overview
- 6.5.3 Samsung Biologics Biologics CDMO Sales, Revenue and Gross Margin (2020-2025)
- 6.5.4 Samsung Biologics Biologics CDMO Product Portfolio
- 6.5.5 Samsung Biologics Recent Developments
- 6.6 Toyobo
- 6.6.1 Toyobo Comapny Information
- 6.6.2 Toyobo Business Overview
- 6.6.3 Toyobo Biologics CDMO Sales, Revenue and Gross Margin (2020-2025)
- 6.6.4 Toyobo Biologics CDMO Product Portfolio
- 6.6.5 Toyobo Recent Developments
- 6.7 AbbVie
- 6.7.1 AbbVie Comapny Information
- 6.7.2 AbbVie Business Overview
- 6.7.3 AbbVie Biologics CDMO Sales, Revenue and Gross Margin (2020-2025)
- 6.7.4 AbbVie Biologics CDMO Product Portfolio
- 6.7.5 AbbVie Recent Developments
- 6.8 Lonza Group AG
- 6.8.1 Lonza Group AG Comapny Information
- 6.8.2 Lonza Group AG Business Overview
- 6.8.3 Lonza Group AG Biologics CDMO Sales, Revenue and Gross Margin (2020-2025)
- 6.8.4 Lonza Group AG Biologics CDMO Product Portfolio
- 6.8.5 Lonza Group AG Recent Developments
- 6.9 Thermo Fisher Scientific
- 6.9.1 Thermo Fisher Scientific Comapny Information
- 6.9.2 Thermo Fisher Scientific Business Overview
- 6.9.3 Thermo Fisher Scientific Biologics CDMO Sales, Revenue and Gross Margin (2020-2025)
- 6.9.4 Thermo Fisher Scientific Biologics CDMO Product Portfolio
- 6.9.5 Thermo Fisher Scientific Recent Developments
- 6.10 WuXi Biologics
- 6.10.1 WuXi Biologics Comapny Information
- 6.10.2 WuXi Biologics Business Overview
- 6.10.3 WuXi Biologics Biologics CDMO Sales, Revenue and Gross Margin (2020-2025)
- 6.10.4 WuXi Biologics Biologics CDMO Product Portfolio
- 6.10.5 WuXi Biologics Recent Developments
- 7 North America by Country
- 7.1 North America Biologics CDMO Sales by Country
- 7.1.1 North America Biologics CDMO Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 7.1.2 North America Biologics CDMO Sales by Country (2020-2025)
- 7.1.3 North America Biologics CDMO Sales Forecast by Country (2026-2031)
- 7.2 North America Biologics CDMO Market Size by Country
- 7.2.1 North America Biologics CDMO Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 7.2.2 North America Biologics CDMO Market Size by Country (2020-2025)
- 7.2.3 North America Biologics CDMO Market Size Forecast by Country (2026-2031)
- 8 Europe by Country
- 8.1 Europe Biologics CDMO Sales by Country
- 8.1.1 Europe Biologics CDMO Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 8.1.2 Europe Biologics CDMO Sales by Country (2020-2025)
- 8.1.3 Europe Biologics CDMO Sales Forecast by Country (2026-2031)
- 8.2 Europe Biologics CDMO Market Size by Country
- 8.2.1 Europe Biologics CDMO Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 8.2.2 Europe Biologics CDMO Market Size by Country (2020-2025)
- 8.2.3 Europe Biologics CDMO Market Size Forecast by Country (2026-2031)
- 9 Asia-Pacific by Country
- 9.1 Asia-Pacific Biologics CDMO Sales by Country
- 9.1.1 Asia-Pacific Biologics CDMO Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 9.1.2 Asia-Pacific Biologics CDMO Sales by Country (2020-2025)
- 9.1.3 Asia-Pacific Biologics CDMO Sales Forecast by Country (2026-2031)
- 9.2 Asia-Pacific Biologics CDMO Market Size by Country
- 9.2.1 Asia-Pacific Biologics CDMO Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 9.2.2 Asia-Pacific Biologics CDMO Market Size by Country (2020-2025)
- 9.2.3 Asia-Pacific Biologics CDMO Market Size Forecast by Country (2026-2031)
- 10 South America by Country
- 10.1 South America Biologics CDMO Sales by Country
- 10.1.1 South America Biologics CDMO Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 10.1.2 South America Biologics CDMO Sales by Country (2020-2025)
- 10.1.3 South America Biologics CDMO Sales Forecast by Country (2026-2031)
- 10.2 South America Biologics CDMO Market Size by Country
- 10.2.1 South America Biologics CDMO Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 10.2.2 South America Biologics CDMO Market Size by Country (2020-2025)
- 10.2.3 South America Biologics CDMO Market Size Forecast by Country (2026-2031)
- 11 Middle East and Africa by Country
- 11.1 Middle East and Africa Biologics CDMO Sales by Country
- 11.1.1 Middle East and Africa Biologics CDMO Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 11.1.2 Middle East and Africa Biologics CDMO Sales by Country (2020-2025)
- 11.1.3 Middle East and Africa Biologics CDMO Sales Forecast by Country (2026-2031)
- 11.2 Middle East and Africa Biologics CDMO Market Size by Country
- 11.2.1 Middle East and Africa Biologics CDMO Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 11.2.2 Middle East and Africa Biologics CDMO Market Size by Country (2020-2025)
- 11.2.3 Middle East and Africa Biologics CDMO Market Size Forecast by Country (2026-2031)
- 12 Value Chain and Sales Channels Analysis
- 12.1 Biologics CDMO Value Chain Analysis
- 12.1.1 Biologics CDMO Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 Biologics CDMO Production Mode & Process
- 12.2 Biologics CDMO Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 Biologics CDMO Distributors
- 12.2.3 Biologics CDMO Customers
- 13 Concluding Insights
- 14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.